Indian court weighs broader use of 16% retail margin amid drug-pricing debate

Key Facts

The case before India’s Supreme Court focused on drug-pricing rules and sales margins after the court asked the government on September 29 why the 16% retail margin was not applied more broadly. The question forms part of judicial proceedings to review price differences and margins, and does not constitute an order imposing a uniform cap on all medicines. Under the regulatory framework, the National Pharmaceutical Pricing Authority calculates the ceiling price of a scheduled drug by taking the average retail selling prices of eligible formulations and then adding the 16% retail margin. The debate therefore concerns the scope of the existing pricing formula, not an enforceable court ruling requiring that margin for all products. The court cited a cancer drug with a maximum consumer price of about 27,000 rupees, although its price to the trader was about 2,700 rupees.

At a hearing on October 12, the government said it had set trade margins for anti-cancer drugs at 30% of the maximum retail price. The court’s discussion extended to whether margin controls should cover other medicines and medical devices after the government presented the measure for cancer drugs. That specific measure raises a broader question about the scope of regulation, without implying that the court had ruled to expand it. Additional Solicitor General Aishwarya Bhati said the government did not want to control the entire pharmaceutical system. She added: "If government intervention is excessive, the market will suffer, and that will affect the availability of medicines."

The court set October 27 as the next hearing date during its October 12 session. The date concerns the continuation of consideration of the issue and does not establish that a new ruling was issued that day. The main regulatory question remains whether margin controls will be limited to cancer drugs or extended to other categories. The 16% margin also remains part of the formula for calculating ceiling prices for scheduled drugs, while the government cited a separate 30% cap for cancer drugs. This distinction between the existing pricing formula and the specific government measure makes the scope of any subsequent change central to the case.

In the available closing data for Fortis Healthcare, the stock closed at 55.81 on October 20, then 55.97 on October 21. The close rose to 57.88 on October 22 and 57.95 on October 23, before reaching 57.53 on October 26. This is the latest reading in the supplied record and does not include an October 27 close. In broader economic activity, India’s flash composite purchasing managers’ index rose to 56.7 points in October from 55.9 in September, exceeding the Reuters poll median forecast of 56.1. These figures provide context for India’s markets and economy, while the path of drug-price regulation remains tied to the outcome of the case proceedings.